Mount Sinai Hospital: Edoxaban May Be Effective Treatment for Atrial Fibrillation After Transcatheter Aortic Valve Replacement
August 31, 2021
August 31, 2021
NEW YORK, Aug. 31 (TNSJou) -- Mount Sinai Hospital issued the following news release:
The anticoagulant edoxaban may be just as effective as warfarin for preventing heart attack or stroke in patients with atrial fibrillation (AF) who undergo transcatheter aortic valve replacement (TAVR), according to a large-scale international study led by Mount Sinai.
The ENVISAGE-TAVI AF trial is the largest to investigate an edoxaban-based strategy in this patient population compare . . .
The anticoagulant edoxaban may be just as effective as warfarin for preventing heart attack or stroke in patients with atrial fibrillation (AF) who undergo transcatheter aortic valve replacement (TAVR), according to a large-scale international study led by Mount Sinai.
The ENVISAGE-TAVI AF trial is the largest to investigate an edoxaban-based strategy in this patient population compare . . .